Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$135.36 +0.7%	$132.82	$99.71 ▼ $141.23	$235.63B	0.73	6.13 million shs	710,488 shs
AZN AstraZeneca	$69.64 -0.3%	$70.59	$61.24 ▼ $87.68	$216.50B	0.38	5.21 million shs	867,649 shs
MRK Merck & Co., Inc.	$78.91 -0.2%	$79.06	$73.31 ▼ $129.93	$198.33B	0.38	13.12 million shs	2.83 million shs
NVS Novartis	$120.62 +0.5%	$113.95	$96.06 ▼ $121.19	$255.17B	0.59	1.58 million shs	276,187 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	+1.14%	+0.53%	+1.23%	+29.34%
AZN AstraZeneca	0.00%	-0.14%	-4.08%	-4.97%	-10.44%
MRK Merck & Co., Inc.	0.00%	-0.40%	+2.69%	-12.05%	-36.24%
NVS Novartis	0.00%	+4.05%	+4.00%	+7.91%	+13.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.886 of 5 stars	2.4	3.0	4.2	4.5	3.0	2.5	2.5
AZN AstraZeneca	2.2938 of 5 stars	2.4	3.0	1.7	0.0	2.9	0.0	1.3
MRK Merck & Co., Inc.	4.9948 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
NVS Novartis	1.645 of 5 stars	1.0	3.0	2.5	0.0	2.8	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.76	Moderate Buy	$142.61	5.36% Upside
AZN AstraZeneca	2.83	Moderate Buy	$85.00	22.07% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	38.38% Upside
NVS Novartis	2.00	Hold	$123.38	2.29% Upside

Current Analyst Ratings Breakdown

Latest NVS, AZN, ABT, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
4/22/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$85.00
4/17/2025	ABT Abbott Laboratories	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$133.00 ➝ $145.00
4/17/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$132.00 ➝ $142.00
4/17/2025	ABT Abbott Laboratories	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$140.00 ➝ $145.00
4/17/2025	ABT Abbott Laboratories	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$117.00 ➝ $127.00
4/17/2025	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$136.00 ➝ $147.00
4/17/2025	ABT Abbott Laboratories	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$158.00 ➝ $159.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.61	$6.63 per share	20.41	$27.62 per share	4.90
AZN AstraZeneca	$54.07B	3.99	$6.27 per share	11.10	$13.18 per share	5.28
MRK Merck & Co., Inc.	$64.17B	3.09	$9.44 per share	8.36	$18.33 per share	4.30
NVS Novartis	$50.32B	5.06	$10.75 per share	11.22	$21.59 per share	5.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.71	17.57	23.62	2.55	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	28.04	13.93	1.28	14.14%	33.14%	12.83%	7/24/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.50	7.97	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	18.87	13.69	1.73	24.70%	39.44%	16.43%	7/17/2025 (Estimated)

Latest NVS, AZN, ABT, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	N/A	N/A
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.74%	N/A	30.61%	54 Years
AZN AstraZeneca	$2.06	2.96%	N/A	82.73%	N/A
MRK Merck & Co., Inc.	$3.24	4.11%	N/A	47.16%	14 Years
NVS Novartis	$2.60	2.16%	N/A	40.63%	N/A

Latest NVS, AZN, ABT, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
AZN AstraZeneca	0.65	0.90	0.70
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVS Novartis	0.56	0.79	0.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
MRK Merck & Co., Inc.	0.09%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable

NVS, AZN, ABT, and MRK Headlines

Recent News About These Companies

Altus Wealth Group LLC Purchases New Stake in Novartis AG (NYSE:NVS)

3 hours ago | marketbeat.com

Novartis AG (NYSE:NVS) Shares Sold by First Fiduciary Investment Counsel Inc.

3 hours ago | marketbeat.com

Novartis AG (NYSE:NVS) Stake Boosted by Joel Isaacson & Co. LLC

June 30 at 5:21 AM | marketbeat.com

7 Killer European Stocks To Buy In July

June 29 at 10:52 AM | 247wallst.com

4,702 Shares in Novartis AG (NYSE:NVS) Bought by Guerra Advisors Inc

June 29 at 7:39 AM | marketbeat.com

BSW Wealth Partners Has $401,000 Stock Holdings in Novartis AG (NYSE:NVS)

June 29 at 5:13 AM | marketbeat.com

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

June 28 at 12:45 PM | insidermonkey.com

Mirae Asset Global Investments Co. Ltd. Has $47.87 Million Holdings in Novartis AG (NYSE:NVS)

June 28 at 5:43 AM | marketbeat.com

Sequoia Financial Advisors LLC Has $3.65 Million Stake in Novartis AG (NYSE:NVS)

June 28 at 4:27 AM | marketbeat.com

What is Zacks Research's Forecast for Novartis Q1 Earnings?

June 28 at 2:24 AM | americanbankingnews.com

Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

June 27 at 11:47 PM | pmlive.comP

Bartlett & CO. Wealth Management LLC Has $9.84 Million Holdings in Novartis AG (NYSE:NVS)

June 27 at 7:47 AM | marketbeat.com

Q2 Earnings Estimate for Novartis Issued By Zacks Research

June 27 at 6:19 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Sold by Cambridge Investment Research Advisors Inc.

June 27 at 3:47 AM | marketbeat.com

Novartis, ProFound Therapeutics Ink Multi-Year Collaboration to Target Cardiovascular Disease Proteins

June 27 at 3:26 AM | genengnews.comG

Novartis and Cannes Can: Diversity Collective Team Up To Address Racial Health Disparities

June 26, 2025 | blackenterprise.comB

Final Trades: Novartis, Sixth Street, Amazon and the IYF

June 26, 2025 | youtube.comY

Novartis inks deal with ProFound on cardio diseases

June 26, 2025 | thepharmaletter.comT

Novartis pens ProFound pact, offering up $750M biobucks per cardiovascular target

June 26, 2025 | fiercebiotech.comF

Kirkland Withdraws From Novartis Case After Regeneron Challenge

June 26, 2025 | news.bloomberglaw.comN

Zacks Research Has Positive Outlook for Novartis Q1 Earnings

June 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS, AZN, ABT, and MRK Company Descriptions

Abbott Laboratories NYSE:ABT

$135.35 +0.98 (+0.73%)

As of 11:16 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$69.64 -0.22 (-0.31%)

As of 11:16 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. NYSE:MRK

$78.90 -0.20 (-0.25%)

As of 11:16 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$120.62 +0.61 (+0.51%)

As of 11:16 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time